Avantor Announces Investment in Manufacturing and Distribution Hub in Singapore to Serve Rapidly Growing Asia Pacific Biopharma Industry

Singapore, May 5, 2022 – (ACN Newswire) – Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, today announced it will create a new manufacturing and distribution Hub in Singapore, by integrating its existing distribution facility with new manufacturing operations. The new Hub, which brings Avantor solutions closer to regional customers and strengthens global supply chain capabilities, will be fully operational early next year.


Avantor announced it will create a new Manufacturing and Distribution Hub in Singapore by integrating its existing distribution facility with new manufacturing operations.


"The Singapore Manufacturing and Distribution Hub will enable Avantor to better serve the fast-growing Asia Pacific Biopharma market by facilitating shorter lead times, enhancing supply chain security and increasing capacity in the region," said Christophe Couturier, Executive Vice President, AMEA, Avantor. "The Hub will boost regional innovation and serve as an industry benchmark for Singapore and Asia Pacific's global quality and regulatory standards, and demonstrates Avantor's commitment to growing our presence in the region."

The new Hub will provide a range of services including quality control and inventory management expertise, and feature cGMP manufacturing suites and testing labs for process ingredients and excipients.

About Avantor

Avantor, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world.

For more information, visit https://news.avantorsciences.com/home and find us on:
LinkedIn: https://www.linkedin.com/company/avantorinc/
Twitter: https://twitter.com/Avantor_News
Facebook: https://www.facebook.com/Avantorinc/

Regional Media Contact
Christina Koh
Director, Communications – AMEA
Avantor
M: +65 9720 0169
Christina.Koh@avantorsciences.com

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Cryoviva Singapore Expands Cord Blood Banking Services to Bahrain

Singapore, Sep 7, 2021 – (ACN Newswire) – Local family cord blood bank Cryoviva Singapore (https://cryoviva.com.sg) is continuing with its rapid geographic growth plans with an entry into the Bahrain market. This latest new market entry closely follows Cryoviva establishing a footprint in Dubai to serve couples in the UAE that are on the family way.


Rajesh Nair, CEO of Cryoviva Singapore


"It fills the entire Cryoviva team with a great sense of pride and satisfaction to help customers in Bahrain and add another nation to the list of countries we serve from Singapore. We are steadfastly focused on our goal to give every family the chance to benefit from the medical potential of cord component stem cells should they ever need it. Every new market we enter and serve successfully is another step closer to that goal," says Rajesh Nair, CEO of Cryoviva Singapore.

"Our excellent credentials as a well-established cord blood bank with a proven track record, experienced medical and management teams and strong investor backing make us a reliable and trustworthy provider for young families in Bahrain. Equally importantly, I believe that customers in Bahrain get considerable confidence and reassurance from Singapore's reputation for world-class facilities and strict adherence to high quality standards. We look forward to collaborating with healthcare providers in Bahrain offering maternity services to offer greater service to their valued patients."

Rajesh believes that while Cryoviva continues with its expansion plans into more countries in the Middle East and ASEAN, Singapore continues to be extremely important for the company. "While we have made considerable progress in the relatively short span of 7 years here, we are striving hard to be the top family cord blood bank in Singapore. We strongly believe in the immense potential for growth in cord blood banking here and are confident that our expertise, experience and delivery of top-notch customer service will contribute to convincing more families on the long-term healthcare benefits of the services we offer."

About Cryoviva Singapore

Established in 2014, Cryoviva (https://cryoviva.com.sg) is a reputed family cord blood bank in Singapore. The company is part of an international group that is backed by reputed multinational investor organisations. The Cryoviva group has successfully stored over 160,000 umbilical cord blood units. Cryoviva's cord blood storage facility in Singapore is MoH-licensed, AABB accredited and IS ISO 9001:2015 QMS Certified, testaments to the stringent processes and quality standards that it adheres to. Thanks to being centrally located and proximity to most major maternity hospitals in Singapore, cord blood samples reach its facilities very quickly and efficiently to ensure top quality maintenance upon storage.

Media Contact:
Krish Sharma, General Manager, Cryoviva Singapore
Tel: +65-9651 7080
E-mail: krish@cryoviva.com.sg

Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Witness Twelve MedTech Startups showcasing latest HealthTech Innovations

TAIPEI, TW, Aug 23, 2021 – (ACN Newswire) – SC Hospital (SCMH) and IRCAD Taiwan are collaborating with BE Accelerator, the largest healthcare accelerator in Asia, to present Batch 5, 'DemoDay 2021: Applied Technologies for Minimally Invasive Surgery'. It's the celebration of 12 brilliant startups x 24 intensive weeks, sharing their applied technologies and solutions for minimally invasive surgery, medical devices, and AI-based healthcare, shaping the future of the industry today.



Incubated for 24 weeks, the twelve startups and accelerator teams collaborated with mentors and partners to make this acceleration program remarkable. As the world marks a year and a half of intense disruption by the COVID pandemic, our teams demonstrated extraordinary resilience in coming up with significant innovative solutions through the digital transformation of our program.

We are excited to host this year's Demo Day, live and online August 28, celebrating the progress of our twelve startups as they graduate from our 24-week Proof of Concept (POC) program, to explore opportunities for new programs or offering Health-Tech and further MedTech collaboration. [https://reurl.cc/EnAG9m].

Our 12 accomplished startups from Taiwan, Thailand, and Canada :

– EPED, Inc., Taiwan
A leader in the field of minimally invasive surgery, developing real-time, adaptive medical and dental navigation systems and solutions, with augmented reality AR-based technologies for precision medicine and education.

– Meticuly Co., Ltd., Thailand
Thailand based startup, provider of personalized, cutting-edge 3D printing implant solutions for bone-related surgeries. The end-to-end platform produces personalized bone implants with SLM 3D printing technology.

– Asia PathoGenomics, Inc., Taiwan
Startup providing high throughput, precision pathogen detection services called Metagenomic Next-Generation Sequencing (mNGS). The non-culture based, hypothesis-free precision diagnosis of infectious diseases provides early identification of pathogens and allows for rapid adjustment of therapies.

– Dot Space Biotechnology, Taiwan
Startup involved in measuring intra-abdominal pressure for the clinical prevention of Acute Compartment Syndrome. The system consists of an abdominal capsulized pressure detector/sensor that can be swallowed by patients for continuous measurement of intra-abdominal pressure.

– INOPASE, Japan
Entrepreneurial concept with wireless miniaturized implant neuromodulation for Overactive Bladder (OAB) and Fecal Incontinence (FI) treatment. Current implant neuromodulation requires multiple implantation surgeries and still has additional safety issues, INOPASE is closing the gap to improve the treatment efficacy.

– Medscope Biotech Co., Ltd., Taiwan
Brilliant startup that minimizes the risk during Minimally Invasive Surgery, or MIS. created a 15 degrees slope design for better visibility. Anti-drop jaw design helps ensure a surgeon won't drop e,tra clips during operations (which happens occasionally..).

– Protect Biotech Co. Ltd., Taiwan
Committed to the research and development of companion animal immunotherapy drugs, to become the leader in pet disease immunotherapy in the Pan-Asia region. Protect Biotech currently has the world's first broad-spectrum animal cancer treatment product PT001, ready to enter clinical trials.

– Wiseger Corp., Taiwan
Innovative concept that develops biochemical detecting systems with microfluidic technology. Wisergers is committed to supplying affordable, fast and convenient products for biochemical detection for food safety and blood tests.

– Smart Surgery Technology Co., Ltd., Taiwan
Startup that improves the quality of surgeries and records surgical procedures intensively. Smart Surgery's visual computing AI model includes a surgery simulation system, automatic medical image labelling and a surgery assistance system to better facilitate education in surgical operations.

– Point Robotics MedTech, Inc., Taiwan
Operating room innovations and minimally invasive solutions that reduce variability in surgery, lower surgery risks, reduce medical costs, shorten recovery times and improve precision in surgeries.

– AltumView Systems, Canada
Canada-based AI startup that focuses on the development of smart vision technology for elderly care, rehabilitation, behavioral and cognitive health solutions. Seminare is a revolutionary smart activity sensor for senior care.

– HemoCath, Canada
Another Canada-based startup that guides diagnosis, treatment, and monitoring of inpatients and outpatients with heart failure (HF). HemoCath Intelligent HF Monitoring Platform reduces hospital length of stay and rehospitalization.

Registration
All participants of the virtual demo day will have access to the event live and the recorded video. Moreover, we will have an exclusive campaign for registered VIPs in our mailing list, including VIP booklets files and the opportunity to attend 1-1 facilitated introductions with the founders.

Please RSVP to be included in the VIP mailing list at https://pse.is/3m2uu9
When ticket purchases are completed, you are able to enter the live stream directly from the ticket page.

Show Chwan x BE Demo Day 2021 : Sat, Aug 28 14:00~16:30 P.M. UTC+8

Batch 5 Agenda
14:00 – 14:05 Opening
14:05 – 14:08 Opening Remarks
14:08 – 14:18 SCMH x BE Introduction
14:18 – 14:25 David & Thomas
14:25 – 15:10 Pitch Session
15:10 – 15:20 Break
15:20 – 16:20 Pitch Session
16:20 – 16:30 Dr. Lee panel

An event by IRCAD Taiwan and BE Accelerator:
https://www.beaccelerator.com.tw/
https://www.facebook.com/beaccelerator/
https://www.linkedin.com/company/be-accelerator/
https://www.instagram.com/be_accelerator_tw/

About BE Accelerator
BE Accelerator is the leading biomedical venture capital fund and venture accelerator in Taiwan, focused on early-stage biomedical start-ups entering the Asian market, has nurtured 72 biomedical start-ups thru 5 editions (8/2021) and assisted teams to raise over US$70 million. We leverage the unique strengths of our thriving ecosystem to position as the "Gateway to Asia for HealthTech and MedTech, Local+International."

BE Accelerator is expanding its local and international biomedical ecosystem, including hospitals, investors, R&D, manufacturing and government to help worthy startups, not only from Taiwan but from across the globe to break into the Asian market. Visit www.beaccelerator.com.tw.

About SCMH – Show Chwan Memorial Hospital
'Show Chwan' originated with the commemoration of President Huang Min-Ho's late father. It represents an aspiration to show concern for the elderly, love for the young, and care for everyone's health. Show Chwan is a hand-in-hand family healthcare system currently with eight hospitals. For medical and healthcare, President Huang advocates the spirit of Mayo Clinic in establishing a sound rural hospital system, allowing people in the most remote areas to enjoy the quality medical care found in cosmopolitan cities. Visit www.scmh.org.tw.

About IRCAD Taiwan
In 1994, IRCAD opened on the grounds of the University Hospital of Strasbourg, gaining renown over the years as a leading research, technology and surgical education institute. The Asian Institute of Telesurgery (AITS/IRCAD-Taiwan), created in 2008 under the guidance of IRCAD/EITS, is now an alliance with Show Chwan Health Care System, bringing 800 international experts affiliated with IRCAD/EITS into closer proximity with Asian surgeons, providing the same level of excellence in education while saving time and money in travelling. Tens of thousands of surgeons from the world over have come to IRCAD-Taiwan to obtain high-level skills, find cutting-edge technology and pioneering medical devices. Visit www.ircadtaiwan.com.

Contact:
BE Accelerator
Polly Chen
Polly@behealthventures.com
https://www.beaccelerator.com.tw

Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Avantor Named Best Company in Bioprocessing Excellence for Single-use Solutions and Best Bioprocessing Supplier for Upstream Processing at Biologics Manufacturing Korea 2021

Seoul, Korea, June 25, 2021 – (ACN Newswire) – Avantor, a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies and applied materials industries, was named best company in bioprocessing excellence for single-use solutions and best bioprocessing supplier for upstream processing at Biologics Manufacturing Korea (BMK) 2021.

Sang Kyu Lee, Representative Director – Avantor Korea/Japan(centre), Jin Young Lee, Biopharma Business Manager – Avantor Korea/Japan(left), James Hwang, Innovation Center Field Application & Education Manager – Avantor Korea/Japan(right), after receiving the Awards for Best Company in Single-use Solutions and Upstream Processing at BMK 2021.

This is the second consecutive year Avantor has been selected as the best company in the single-use category at BMK. As the development and supply of biopharmaceuticals, including COVID-19 vaccines and therapeutics, become more important than ever, Avantor has been actively supporting the discovery to delivery of biopharmaceutical therapies to both domestic and foreign pharmaceutical companies. A key piece of this contribution is supplying differentiated upstream solutions such as high-purity materials.

Avantor also has been recognized for its ongoing efforts to develop single-use solutions, which are emerging as the preferred option to improving biopharmaceutical manufacturing processes. Avantor is responding to rapidly increasing needs for treatments and therapies by providing customized solutions to biopharma companies. Avantor closely analyzes manufacturing processes to support customers with increased yield and reduced resources when developing new therapeutics.

SK Lee, Sales Director of Avantor Korea & Japan, said, “We are extremely proud to be recognized by BMK for our leadership in bioprocessing development by providing solutions to biopharmaceutical manufacturers. Working closely with our customers, we play a critical role in enabling breakthroughs in life-changing biologics.”

Narayana Rao Rapolu, Vice President, Biopharma Asia Middle East & Africa for Avantor said, “Avantor’s continued investment in single-use solutions, including our recent acquisition of RIM Bio, with manufacturing capabilities in China, go a long way to demonstrate our commitment to delivering bioprocessing excellence. Our process development and optimization capabilities carried out by our dedicated expert researchers at our Korea Innovation Center is helping customers deliver on cost and time efficiencies.”

For more information on Avantor’s single-use solution for biopharmaceutical manufacturing, visit https://youtu.be/mfjZEfO_RVM.

About Avantor

Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. For information, visit and find us on LinkedIn, Twitter and Facebook.

About Biologics Manufacturing Korea Excellence Award 2021

The Biologics Manufacturing Korea Excellence Award seeks to give recognition to exceptional bioprocessing experts, organizations and technologies that facilitate biomanufacturing excellence with enhanced speed, reduced cost, and superior quality. 2021 marks the tenth year of ABEA. The BMK Awards is part of the Asia-Pacific Bioprocessing Excellence Awards (ABEA) which seeks to recognize organizations within Korea who have engaged in substantial efforts to innovate, optimize processes and uphold a high level of efficacy, quality and safety in biological products manufacturing.

AMEA Media Contact
Christina Koh
Director – Communications, AMEA
Avantor
Phone: +65 9170 0169
Email: Christina.Koh@avantorsciences.com



Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

World-first Hip Fracture Registry Toolbox striving to improve care for the 1 million+ who fracture a hip in Asia Pacific each year

An innovative world-first Hip Fracture Registry Toolbox has been launched today (Tuesday, June 15, 2021) to address the alarming death and disability caused by the more than 1 million hip fractures sustained in the Asia Pacific each year.(1)

Developed by the Asia Pacific Fragility Fracture Alliance (APFFA) in collaboration with the Fragility Fracture Network (FFN), the practical and informative resource explains the fundamental need, and how to best advocate for, the establishment of a national hip fracture registry. Tailored to clinicians, hospital administrators, healthcare systems and governments alike, the Toolbox covers pertinent topics, including stakeholder engagement and consolidation, building a case for change, planning and funding a registry, to setting up a pilot registry and navigating governance and ethics approval. Examples of current registries and other useful resources also feature in the Toolbox.

Concerningly, one-in-four patients who sustain a hip fracture die within a year, and less than half of those who survive, regain their previous level of function.(2-5) The expected direct incurred cost associated with the more than 1.1 million hip fractures estimated to have occurred in nine countries and regions in APAC, including China, Chinese Taipei, Hong Kong SAR, India, Japan, Malaysia, Singapore, South Korea and Thailand in 2018, amounts to USD 7.5 billion. This cost is projected to increase to almost USD 13 billion by 2050.(1)

According to Consultant Ortho-Geriatrician, Clinical Director of the Falls, Balance and Injury Research Centre at Neuroscience Research Australia (NeuRA), and APFFA Hip Fracture Registry Working Group Co-Chair, Professor Jacqui Close, Australia, widescale implementation of hip fracture registries worldwide, can facilitate vast improvements in care for the millions of people who sustain a hip fracture each year.(6,7)

“Hospitals can utilise hip fracture registries to benchmark their provision of care against best practice clinical standards for acute care, rehabilitation, and secondary fracture prevention.(6,8)

“Furthermore, hip fracture registries can transform patient-level data into information that both equips and empowers hospital teams to identify, and develop solutions for key challenges within their respective institutions, and to strive for ongoing improvement in care,”(8) said Prof Close.

By 2050, one in four people in APAC will be aged over 60. This portion of the population is expected to triple between 2010 and 2050, reaching close to 1.3 billion people.(9) Within the same timeframe, between 4.5 to 6.3 million hip fractures are predicted to occur worldwide, half of which will occur in Asia.(10)

Given the exponential increase in both the incidence and costs associated with hip fractures to date, and those anticipated globally,(11) hip fracture registries serve as a vital tool underpinning quality improvement initiatives(8) in the Asia Pacific region, and globally, argues Consultant Geriatrician and Medical Director, Fiona Stanley Fremantle Hospitals Group, and APFFA Hip Fracture Registry Working Group Co-Chair, Dr Hannah Seymour, Australia.

“As of April 2021, 18 countries across Asia Pacific, Europe, Latin America and North America had established a hip fracture registry, at different stages of maturation, participation and development.(12-28) Notably, only three registries are currently operating in the Asia Pacific.

“The Hip Fracture Registry Toolbox explains how timely, reliable and constructive feedback to clinical teams, coupled with the engagement and participation of key stakeholders, improves the impact of hip fracture registries,” Dr Seymour said.

With adequate operational efficiency and funding, registries can improve healthcare, and are likely to prove significantly cost-effective.(29)

Registries can contribute to government initiatives designed to manage rapidly aging populations, and can further help governments to promote the equitable provision of care.(30)

According to Orthopaedic Surgeon and APFFA co-Chair, Dato’ Dr. Joon-Kiong Lee, Malaysia, today’s release of the Toolbox also coincides with the launch of APFFA’s YouTube channel.

“The APFFA YouTube channel will house a series of educational videos featuring interviews with leading clinicians from the Asia Pacific bone arena, reflecting on important considerations for each of the seven key steps involved in establishing a hip fracture registry.

“We trust our APFFA and FFN Toolbox, and supporting videos, will arm our colleagues throughout Asia Pacific, and the rest of the world, with the necessary inspiration, knowledge and guidance on how to successfully establish a national hip fracture registry in their respective countries,” said Dato’ Dr Lee.

About APFFA

Formed in November 2018, APFFA comprises seven global and regional member organisations from the geriatrics, orthopaedics, osteoporosis and rehabilitation sectors, with the primary purpose of driving policy change, improving awareness and changing political and professional mindsets, to facilitate optimal fragility fracture management across Asia Pacific.

About the APFFA HFR Working Group

The APFFA Hip Fracture Registry Working Group is a principal action group within APFFA, comprising global experts in hip fracture treatment and management, charged with driving the development of the HFR Toolbox.

In addition, the HFRWG report on hip fracture epidemiology and outcomes across Asia Pacific aims to frame the problems facing the region, and outline APFFA-related projects capable of providing a part solution to these issues.

The HFRWG is also responsible for a feasibility study examining the costs and practicalities of establishing new hip fracture registries in specific countries throughout Asia Pacific.

About the Fragility Fracture Network (FFN)

The FFN is a global organisation comprising a multidisciplinary network of experts charged with improving the treatment and secondary prevention of fragility fractures. The organisation strives to optimise multidisciplinary management of a patient with a fragility fracture, to ensure maximum recovery, quality of life, and no further fractures, worldwide.

The Hip Fracture Audit Special Interest Group (HFA SIG) comprises a multidisciplinary network of clinicians well-versed in hip fracture audits, striving for global adoption of a Minimum Common Dataset (MCD), and a worldwide platform to share HFA knowledge, learning and research.

To learn more about APFFA, and to download the Hip Fracture Registry Toolbox, head to www.apfracturealliance.org/HFR-toolbox/

Follow APFFA on LinkedIn: asia-pacific-fragility-fracture-alliance.

For more information, contact:
Kirsten Bruce or Mel Kheradi, VIVA! Communications, Sydney, AUSTRALIA
T. +61 401 717 566 / +61 2 421 551 257
E. kirstenbruce@vivacommunications.com.au / melorin@vivacommunications.com.au

Download the Hip Fracture Registry Toolbox digital media kit: www.apfracturealliance.org/hfr-toolbox-media-kit/

References
1. Cheung, C.-L., et al., An updated hip fracture projection in Asia: The Asian Federation of Osteoporosis Societies study. Osteoporosis and sarcopenia, 2018. 4(1): p. 16-21.
2. National Osteoporosis Foundation, NOF’s Clinician’s Guide to Prevention and Treatment of Osteoporosis.
3. Australian Institute of Health and Welfare. Musculoskeletal fact sheet. Osteoporosis. [cited Jan 2020]; Available from: https://www.aihw.gov.au/getmedia/61866386-568b-41fa-93e4-090ad201ab2b/phe187-osteoporosis-factsheet.pdf.aspx
4. Cosman, F., et al., Clinician’s Guide to Prevention and Treatment of Osteoporosis. Osteoporosis international: a journal established as a result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2014. 25(10): p. 2359-2381.
5. Downey, C., M. Kelly, and J.F. Quinlan, Changing trends in the mortality rate at 1-year post-hip fracture – a systematic review. World Journal of Orthopaedics, 2019. 10(3): p. 166-175.
6. Currie, C., Hip fracture audit: Creating a critical mass of expertise and enthusiasm for hip fracture care. Injury, 2018. 49(8): p. 1418-1423.
7. Wise, J., Hip fracture audit may have saved 1000 lives since 2007. BMJ: British Medical Journal, 2015. 351: p. h3854.
8. Johansen, A., et al., Using national hip fracture registries and audit databases to develop an international perspective. Injury, 2017. 48(10): p. 2174-2179.
9. United Nation Population Fund (UNFPA) Asia & the Pacific. Ageing. [cited May]; Available from: https://asiapacific.unfpa.org/en/node/15208.
10. Cheung, C.L., et al., An updated hip fracture projection in Asia: The Asian Federation of Osteoporosis Societies study. Osteoporos Sarcopenia, 2018. 4(1): p. 16-21.
11. Baker, P.N., et al., Evolution of the hip fracture population: time to consider the future? A retrospective observational analysis. BMJ Open, 2014. 4(4): p. e004405.
12. Asia Pacific Fragility Fracture Alliance. Hip Fracture Registry Toolbox. 2021 [cited May 2021]; Available from: www.apfracturealliance.org/HFR-toolbox/
13. Australia and New Zealand Hip Fracture Registry. Australia and New Zealand Hip Fracture Registry. [cited May 2021]; Available from: https://anzhfr.org.
14. Yamamoto, N., H.E. Takahashi, and N. Endo, Chapter 6 – The Challenge of Secondary Prevention of Hip Fracture in Japan, in Secondary Fracture Prevention, M.J. Seibel and P.J. Mitchell, Editors. 2019, Academic Press. p. 109-115.
15. Kim, J.W., et al., Reoperation rate, mortality and ambulatory ability after internal fixation versus hemiarthroplasty for unstable intertrochanteric fractures in elderly patients: a study on Korean Hip Fracture Registry. Arch Orthop Trauma Surg, 2020. 140(11): p. 1611-1618.
16. Schoeneberg, C., et al., Effect of time-to-surgery on in-house mortality during orthogeriatric treatment following hip fracture: A retrospective analysis of prospectively collected data from 16,236 patients of the AltersTraumaRegister DGU®. Injury, 2021. 52(3): p. 554-561.
17. Kristensen, P.K., et al., The Danish Multidisciplinary Hip Fracture Registry 13-Year Results from a Population-Based Cohort of Hip Fracture Patients. Clin Epidemiol, 2020. 12: p. 9-21.
18. Sund, R., et al., Monitoring the performance of hip fracture treatment in Finland. Annals of Medicine, 2011. 43(sup1): p. S39-S46.
19. Yli-Kyyny, T.T., et al., Risk factors for early readmission due to surgical complications after treatment of proximal femoral fractures – A Finnish National Database study of 68,800 patients. Injury, 2019. 50(2): p. 403-408.
20. Walsh, M.E., et al., Trends in hip fracture care in the Republic of Ireland from 2013 to 2018: results from the Irish Hip Fracture Database. Osteoporos Int, 2021. 32(4): p. 727-736.
21. Finnish Institute for health and welfare. PERFECT Hip Fracture Registry Available from: https://thl.fi/fi/tutkimus-ja-kehittaminen/tutkimukset-ja-hankkeet/perfect/osahankkeet/lonkkamurtuma/perusraportit.
22. Ferrara, M.C., et al., Three-year National report from the Gruppo Italiano di Ortogeriatria (GIOG) in the management of hip-fractured patients. Aging Clin Exp Res, 2020. 32(7): p. 1245-1253.
23. van Voorden, T.A.J., et al., Effect of the Dutch Hip Fracture Audit implementation on mortality, length of hospital stay and time until surgery in elderly hip fracture patients; a multi-centre cohort study. Injury, 2020. 51(4): p. 1038-1044.
24. Kristoffersen, M.H., et al., Cognitive impairment influences the risk of reoperation after hip fracture surgery: results of 87,573 operations reported to the Norwegian Hip Fracture Register. Acta Orthop, 2020. 91(2): p. 146-151.
25. The Scottish Hip Fracture Audit. The Scottish Hip Fracture Audit. [cited May 2021]; Available from: https://www.shfa.scot.nhs.uk.
26. Ojeda-Thies, C., et al., Spanish National Hip Fracture Registry (RNFC): analysis of its first annual report and international comparison with other established registries. Osteoporos Int, 2019. 30(6): p. 1243-1254.
27. Jc, V., et al., Mexican Hip Fracture Audit (ReMexFC): objectives and methodology. MOJ Orthopedics & Rheumatology, 2019. 11: p. 115-118.
28. Arshi, A., et al., Standardized Hospital-Based Care Programs Improve Geriatric Hip Fracture Outcomes: An Analysis of the ACS NSQIP Targeted Hip Fracture Series. J Orthop Trauma, 2019. 33(6): p. e223-e228.
29. Australian Commission on Safety and Quality in Health Care, Economic evaluation of clinical quality registries. 2016.
30. Australian Government, National Clinical Quality Registry and Virtual Registry Strategy – A National Strategy for Clinical Quality Registries and Virtual Registries 2020-2030. 2020.


Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

World-first Hip Fracture Registry Toolbox striving to improve care for the 1 million+ who fracture a hip in Asia Pacific each year

MALAYSIA, Jun 15, 2021 – (ACN Newswire) – An innovative world-first Hip Fracture Registry Toolbox has been launched today (June 15) to address the alarming deaths and disabilities caused by the more than 1 million hip fractures sustained in the Asia Pacific each year.



Developed by the Asia Pacific Fragility Fracture Alliance (APFFA) in collaboration with the Fragility Fracture Network (FFN), the practical and informative resource explains the fundamental need, and how to best advocate for, the establishment of a national hip fracture registry.

Tailored to clinicians, hospital administrators, healthcare systems and governments alike, the Toolbox covers pertinent topics, including stakeholder engagement and consolidation, building a case for change, and planning and funding a registry, to setting up a pilot registry, and navigating governance and ethics approval. Examples of current registries and other useful resources also feature in the Toolbox.

Concerningly, one-in-four patients who sustain a hip fracture die within a year, and less than half of those who survive, regain their previous level of function. The expected direct incurred cost associated with the more than 1.1 million hip fractures estimated to have occurred in nine countries and regions in APAC, including China, Chinese Taipei, Hong Kong SAR, India, Japan, Malaysia, Singapore, South Korea and Thailand in 2018, amounts to USD 7.5 billion. This cost is projected to increase to almost USD 13 billion by 2050.

According to Professor Jacqui Close, Consultant Ortho-Geriatrician, and Clinical Director of the Falls, Balance and Injury Research Centre at Neuroscience Research Australia (NeuRA) and APFFA Hip Fracture Registry Working Group Co-Chair, widescale implementation of hip fracture registries worldwide can facilitate vast improvements in care for the millions of people who sustain a hip fracture each year.

"Hospitals can utilise hip fracture registries to benchmark their provision of care against best practice clinical standards for acute care, rehabilitation, and secondary fracture prevention. Hip fracture registries can transform patient-level data into information that both equips and empowers hospital teams to identify, and develop solutions for key challenges within their respective institutions, and to strive for ongoing improvement in care," said Prof Close.

By 2050, one in four people in APAC will be aged over 60. This portion of the population is expected to triple between 2010 and 2050, reaching close to 1.3 billion people. Within the same timeframe, between 4.5 to 6.3 million hip fractures are predicted to occur worldwide, half of which will occur in Asia.

Dr Hannah Seymour, Consultant Geriatrician and Medical Director, Fiona Stanley Fremantle Hospitals Group in Australia, and APFFA Hip Fracture Registry Working Group Co-Chair argues that given the exponential increase in both the incidence and costs associated with hip fractures to date, and those anticipated globally, hip fracture registries serve as a vital tool underpinning quality improvement initiatives in the Asia Pacific region, and globally.

"As of April 2021, 18 countries across Asia Pacific, Europe, Latin America and North America had established a hip fracture registry, at different stages of maturation, participation and development. Notably, only three registries are currently operating in the Asia Pacific.

"The Hip Fracture Registry Toolbox explains how timely, reliable and constructive feedback to clinical teams, coupled with the engagement and participation of key stakeholders, improves the impact of hip fracture registries," Dr Seymour said.

Registries can contribute to government initiatives designed to manage rapidly ageing populations, and can further help governments to promote the equitable provision of care. With adequate operational efficiency and funding, registries can improve healthcare, and are likely to prove significantly cost-effective.

According to Dato' Dr Joon-Kiong Lee, Orthopaedic Surgeon in Malaysia and APFFA co-Chair, today's release of the Toolbox coincides with the launch of APFFA's YouTube channel: "The APFFA YouTube channel will house a series of educational videos featuring interviews with leading clinicians from the Asia Pacific arena, reflecting on important considerations for each of the seven key steps involved in establishing a hip fracture registry.

"We trust our APFFA and FFN Toolbox, and supporting videos, will arm our colleagues throughout Asia Pacific, and the rest of the world, with the necessary inspiration, knowledge and guidance on how to successfully establish a national hip fracture registry in their respective countries," said Dato' Dr Lee.

About APFFA
Formed in November 2018, APFFA comprises seven global and regional member organisations from the geriatrics, orthopaedics, osteoporosis and rehabilitation sectors, with the primary purpose of driving policy change, improving awareness and changing political and professional mindsets, to facilitate optimal fragility fracture management across Asia Pacific. www.apfracturealliance.org.

About the APFFA HFR Working Group
The APFFA Hip Fracture Registry Working Group is a principal action group within APFFA, comprising global experts in hip fracture treatment and management, charged with driving the development of the HFR Toolbox. The HFRWG report on hip fracture epidemiology and outcomes across Asia Pacific aims to frame the problems facing the region, and outline APFFA-related projects capable of providing a partial solution to these issues. The HFRWG is also responsible for a feasibility study examining the costs and practicalities of establishing new hip fracture registries in specific countries throughout Asia Pacific.

About the Fragility Fracture Network (FFN)
The FFN is a global organisation comprising a multidisciplinary network of experts charged with improving the treatment and secondary prevention of fragility fractures. The organisation strives to optimise multidisciplinary management of a patient with a fragility fracture, to ensure maximum recovery, quality of life, and no further fractures, worldwide.

The Hip Fracture Audit Special Interest Group (HFA SIG) comprises a multidisciplinary network of clinicians
well-versed in hip fracture audits, striving for global adoption of a Minimum Common Dataset (MCD), and a worldwide platform to share HFA knowledge, learning and research.

To learn more about APFFA and download the Hip Fracture Registry Toolbox head to: www.apfracturealliance.org/HFR-toolbox/, follow APFFA on LinkedIn: asia-pacific-fragility-fracture-alliance, and YouTube: www.youtube.com/channel/UCpb3uxbr8BQ1vz2KAp8imxw.

For more information, contact:
Kirsten Bruce or Mel Kheradi, VIVA! Communications, Sydney, AUSTRALIA
T. +61 401 717 566 / +61 2 421 551 257
E. kirstenbruce@vivacommunications.com.au / melorin@vivacommunications.com.au

Download the Hip Fracture Registry Toolbox Digital Media Kit:
www.apfracturealliance.org/hfr-toolbox-media-kit/

References:
See all references at https://acnnewswire.com/press-release/english/67278/.

Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Genesis Medtech Group Raises Significant Growth Investment in Latest Round of Series B Financing

SINGAPORE, May 25, 2021 – (ACN Newswire) – Genesis MedTech Group ("Genesis"), a leading medical device company, today announced it has completed its Series B round, raising significant growth financing. General Atlantic, a leading global growth equity firm, led the funding with participation from CITIC Capital and others. The majority of shareholders from Series A followed up with additional investments. Lefei Sun, Managing Director and Head of Healthcare for China at General Atlantic, will join the Genesis Board of Directors.

The funds will be used to drive the research and development of new products and the commercialization of existing products, as well as enable business expansion in emerging markets around the world. This acceleration in Genesis' model is expected to enable patients and healthcare practitioners in emerging markets to access innovative medtech products that can address unmet needs faced day-to-day — Genesis' mission since its inception in 2019.

Meeting Needs Where They Are

Genesis' purpose was born to solve a growing healthcare issue within emerging markets, where increased health problems and demand for medtech solutions are not proportionally addressed by accessible products currently on the market. Despite rapid developments in medtech innovation globally, many of these products remain out of reach for patients and practitioners in these markets.

Genesis seeks to address this issue and has received significant support from innovators worldwide. Its vertically integrated business model, complete with a wide hospital and clinic network, allows for a deep understanding of patients' and practitioners' needs on the ground. Armed with this knowledge, Genesis collaborates with innovators worldwide through an open medtech platform that accelerates meaningful innovations that are cost-effective to meet healthcare needs in these markets.

Warren Wang, Chairman and CEO of Genesis Medtech Group, outlined the importance of collaboration with leading global partners and putting market needs first and foremost: "Our open platform is quintessential in enabling us to bring the world's leading products and technologies to doctors and patients. We will also invest in adding premier talent, consolidating our R&D capabilities, incubating new technologies, and continuing to pursue solutions that answer the real needs of patients and healthcare practitioners — delivering impact where it is needed most."

Lefei Sun, Managing Director and Head of Healthcare for China at General Atlantic, added, "We are excited to help propel the work that Genesis is doing to advance access to healthcare and innovative medical solutions in emerging markets. We believe Genesis' capability set is highly differentiated through the combination of its technology, product and team, with a comprehensive portfolio underpinned by a scalable and integrated platform. This latest round of funding will enable Genesis to continue to tackle disparities in medtech accessibility across global markets. We look forward to partnering with Genesis in this next chapter of its growth."

To date, Genesis' product portfolio includes surgical, neurovascular, peripheral vascular and cardiovascular products. Genesis collaborated with medtech leaders in bringing multiple innovations into China as part of its commitment to making quality healthcare more affordable and accessible for emerging markets.

ABOUT GENESIS MEDTECH GROUP

Genesis MedTech Group is a medical device company headquartered in Singapore. Founded by a group of professionals and entrepreneurs with MedTech experience globally and in Asia, the company's product portfolio focuses on value segment multi-therapy medical device products for emerging markets with sales and distribution through its established commercial network. Genesis MedTech Group covers the entire industry value chain of research and development, production, quality management, supply chain, marketing, and sales.
For more information, visit http://www.genesismedtech.com.

ABOUT GENERAL ATLANTIC

General Atlantic is a leading global growth equity firm providing capital and strategic support for growth companies. Established in 1980, General Atlantic combines a collaborative global approach, sector specific expertise, a long-term investment horizon and a deep understanding of growth drivers to partner with great entrepreneurs and management teams to build market-leading businesses worldwide. General Atlantic has more than 175 investment professionals based in New York, Amsterdam, Beijing, Greenwich, Hong Kong, Jakarta, London, Mexico City, Mumbai, Munich, Palo Alto, Sao Paulo, Shanghai and Singapore. For more information on General Atlantic, please visit the website: www.generalatlantic.com.

For media queries, please contact:

In Singapore:
Karen Chng, Genesis MedTech Group
DID: +65 6865 9879, Email: karen.chng@gmedtech.com

Tracy Huang, Senior Manager, PR and Comms, Genesis MedTech Group
DID: +86 13764630248, Email: tracy.huang@gmedtech.com

Genesis MedTech Group
16 Science Park Drive, #04-03, DNV GL Technology Centre, Singapore 118227
Main Line: +65 68659879, Online: https://www.genesismedtech.com


Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Starting its Industrial Investment in Biotech Companies, China Medical System (0867.HK) has Accelerated its Flywheel of Innovation

HONG KONG, Apr 26, 2021 – (ACN Newswire) – China Medical System Holdings Limited (0867.HK) ("CMS" or the "Company") has been active in the market this year. From the acquisition of Luqa to enter the medical aesthetic market early this year, the Company has attracted the attention of the market. Recently, it has announced the series of agreement signed with Trinomab Biotech Co., Ltd. ("Trinomab"). CMS will make equity investment in Trinomab, and establish a joint venture (the "Joint Venture") with Trinomab, contributed with cash and related products technologies by CMS and Trinomab respectively. The Joint Venture will entrust CMS with the clinical development and commercialization of all its products in Mainland China, Hong Kong, Macau and Taiwan, and Trinomab with the production of all its products. This collaboration marks the beginning of the CMS's industrial investment in cutting-edge biotech companies.

1. What has CMS seen in Trinomab?

The announcement has drawn even more attention from the market and people are curious about why Trinomab has successfully attracted CMS to make collaboration with it.

Established in 2015, Trinomab was jointly founded by the worldwide known expert Dr. Liao Huaxin and the entrepreneur Mr. Zheng Weihong. It is an innovative global biopharmaceutical company dedicated to the R&D of original natural fully human monoclonal antibodies and providing corresponding scientific services.

Trinomab has a new-generation, world-class, core patented technology platform highly regarded in the industry, the natural fully human monoclonal antibody R&D integrated technology platform HitmAb, which is dedicated to the development of original and efficient natural fully human monoclonal antibodies with independent intellectual property rights, suitable for the infectious diseases, autoimmune diseases and malignant tumors, etc.

As the fourth-generation antibody technology, "natural fully human monoclonal antibodies" refers to fully human antibodies derived from natural human B-cell clones or its gene expression. It is marked by high safety, having broad spectrum to foreign pathogens and strong affinity with pathogen targets, which can solve the problem of anti-drug antibody reaction in the clinical use of antibody drugs developed by traditional technologies.

Based on the HitmAb platform, Trinomab has developed more than 20 new native natural fully human monoclonal antibodies, including those against infectious diseases (e.g., rabies virus, tetanus toxin, cytomegalovirus, respiratory syncytial virus, varicella-zoster virus, novel coronavirus, etc.) and cancers among which, certain antibody products are in the process of rapid industrialization.

For example, the Fully Human Hla Antibody of Trinomab contributed to the Joint Venture is a natural fully human antibody against Staphylococcus Aureus (SA) infection, developed via the HitmAb platform, and is now in the preclinical stage. This product neutralizes the alpha-hemolysin (Hla) released by SA to avoid immune downregulation to B cells and to improve immune response. For severe and high-risk patients with SA colonization, compared with antibiotics which are commonly used clinically, Fully Human Hla Antibody of Trinomab has good safety and the preclinical studies have shown good Hla toxin neutralizing activity. It is expected to solve the problems of high mortality, resistance to treatment and side effects from SA infection.

With its HitmAb platform technology, Trinomab is constantly discovering new antibodies to advance the iteration of antibody drugs. In addition to keeping projects that are in line with its own strategy for self-development, Trinomab co-develops the rest with partners in the industry, which gives CMS (0867.HK) the opportunity to make this collaboration. From the announcement of CMS, we can find that other than to the product to be incorporated into the Joint Venture, the two sides will negotiate to promote the priority collaboration on other specific products, so we can expect more projects to be incorporated into the Joint Venture in the future.

In General, Trinomab owns a cutting-edge technology platform and can continue to promote the R&D and production of innovative drugs through the technology platform. While having great development potential, the strength of Trinomab's team is also quite impressive. So why did Trinomab still gladly accept the olive branch passed by CMS?

We believe that although Trinomab has considerable advantages in technology platform and drug R&D, promoting the clinical development and commercialization of new drugs is a major challenge of the channel resources for pharmaceutical companies, and at present, Trinomab does not have the advantages in the clinical and commercialization capabilities, and the accumulation of these capabilities and resources does not happen overnight. Therefore, CMS, which has rich domestic channel resources and strong commercialization ability, chooses to join hands with Trinomab to achieve a win-win combination, which opens up a fast track of commercialization for its subsequent products, and will play an important role in promoting the overall healthy development of Trinomab.

2. Taking this collaboration as a model, CMS will initiate the industrial investment in biotech companies and accelerate the "flywheel" of innovative R&D

From the above, we can see that CMS is precisely interested in the core technology platform of Trinomab. This kind of collaboration is not without a precedent. As early as in 2018-2019, Trinomab had reached cooperation agreements with Changchun BCHT Biotechnology Co. and Wuxi Biologics, etc. It can be seen that the Trinomab's capability of monoclonal antibody drug R&D based on its patented antibody R&D platform has been fully recognized and supported by well-known companies in the industry.

CMS has been working in the industry for many years and has been highly focused on the two core segments of the pharmaceutical industry chain – R&D and marking. CMS' promotion capability is undeniable, with an academic network covering about 57,000 hospitals and medical institutions nationwide and a professional academic promotion team of about 3,300 staffs. And the Company has created leading market positions for its many branded drugs. It also achieved fruitful results in the past through equity investments in overseas biotech companies or strategic cooperation with leading pharmaceutical companies for collaborative R&D. In the past three years, CMS has rapidly acquired more than 20 innovative products with unique and differentiated competitive advantages, such as Diazepam Nasal Spray, Tildrakizumab, Cyclosporine Eye Drops 0.09%, etc., demonstrating its strong innovation ability.

The collaboration with Trinomab is an active exploration of CMS' industrial investment in innovative biopharmaceutical companies. In the past, the Company has always been focusing on overseas markets, but with this collaboration, it also marks the official opening of CMS' industrial investment in domestic cutting-edge biotech companies.

So, what are the features and advantages of this investment?

a. Exploring a new model for industrial investment and building a unique competitive product innovation capability

Unlike simply building its own R&D team or purely introducing products for sale, CMS has been focusing more on the two core parts of the pharmaceutical industry chain, product competence and promotion capability in its past development. Base on this, in the past, to achieve effective integration of pharmaceutical companies and related resources, the Company's product pipeline was often more product-based, that is, to invest in a company for a certain product. It can be seen that so far CMS has invested in the equity of 8 overseas biotech companies and has made strategic cooperation with 6 leading overseas pharmaceutical companies.

CMS has developed strong product selection capability and is able to continuously find innovative drugs with market potential in this path. However, due to the emphasis on product selection, there is no direct relationship between new products, or between the companies the Company invested in, making it difficult to achieve a unified effect. Based on this, CMS further optimized its investment layout and began to focus on cutting-edge technology platforms to explore new products. The benefits of doing so include not only expanding the number and scope of selected products and achieving effective synergy within the platforms, but also forming an organic iteration of innovative products and achieving deep control of the industrial ecology.

From the collaboration with Trinomab, through equity investment + establishment of the joint venture, CMS has made early involvement in the domestic leading technology platform and innovative resources, and advanced its current pipeline of mainly mid- and late-stage products to the early stage, so as to rapidly enrich the innovation pipeline, and realize the expansion from the "point" of investing in innovative drugs as the core to the "extension" of investing in innovative technology platforms, in order to form an industrial investment model that can be rapidly duplicated in the future. Under this model, CMS will actively explore leading technology platforms for cooperation, so as to continuously strengthen its core competitiveness in innovative R&D and introduce cutting-edge innovation results, to build a unique product innovation capability.

b. Achieving complementary advantages and giving full play to CMS' clinical development and commercialization strengths

Behind the Company's industrial investment in domestic cutting-edge biotech companies lies not only its own financial or product selection strength, but also the strengths in innovative R&D and product commercialization.
From the perspective of clinical promotion ability, the completion of clinical enrollment of 220 patients for the blockbuster innovative drug Tildrakizumab in just around two months fully proves that CMS has the hard strength to quickly enroll patients and promote the clinical development with the synergy of its network and expert resources.

In addition, in terms of commercialization ability, the Company has been in the industry for more than 20 years, with its accumulated extensive industry resources, CMS is able to undertake the commercialization of innovative products and achieve rapid sales growth in its efficient operation system, and ultimately achieve an efficient cash flow cycle. CMS' commercialization ability is not purely based on its sales capability, as we can see the Company's selling expense ratio has been maintained at about 22% for years, which is relatively low compared with the industry level, it can be illustrated that CMS is not only very compliant in sales and promotion, but also attached great importance to differentiation advantages and market demands of products rather than blinded innovation, so as to build strengths in its products and brands and achieve win-win for its own economic benefit and the society.

c. Featured with light assets and high efficiency, CMS is aimed at creating VIC model 2.0

At present, there are mainly three models of the innovative drugs R&D in China, namely, big pharma model (independent R&D), biotech model (license in/out) and VIC model (active capital investment).

The big pharma model is often applied to large pharmaceutical companies, as it requires pharmaceutical companies to have sufficient profit-making products to support their investment in R&D. The model requires companies to focus more on the creation of R&D pipeline, as well as the cultivation of research and sales teams, which is apparently an asset-heavy business model.

The biotech model is an R&D model based on drug licensing and development. Under this model, pharmaceutical companies have the key R&D technologies, so they can generate revenue through "License out" clinical stage products, and diversify their R&D pipeline through "License in".

The VIC model is a combination of "VC (venture capital) + IP (intellectual property) + CRO (R&D outsourcing)", which is also known as the active new drug investment model. Under this model, the party that owns the IP receives venture capital, sets up a project-based company, and collaborates with a CRO in R&D. Similar to this model, CMS' industrial investment in innovative biotech companies is featured by being relatively asset-light, low-cost and highly efficient, which can save investment and achieve high cost-effectiveness. For example, with this model, CMS does not need to build its own labs, factories, etc. It acts more as an industry integrator and predator to explore innovative products and technology platforms, and uses its own advantages to integrate resources and continuously realize the incubation and commercialization of innovative products.

The difference between CMS' industrial investment model and VIC model is that the leading party of VIC model is the capital, whose understanding of the industry and contribution to product innovation is very limited. In contrast, CMS' industrial investment is a more advanced version of the VIC model, in which the leading party is CMS. With accumulated resources in the industry for a long time and deeper understanding of products, CMS is more capable of promoting the R&D and commercialization of innovative drugs, and is able to create a systematic, replicable and long-term competitive industrial investment model of innovative drugs. CMS will also build a highly competitive barrier for itself in the industry, and with the maturing of the platform ecology, its business will be expanded and the business potential will be unleashed continuously.

3. Conclusion

Based upon the current situation of China Medical System (0867.HK), its existing business has maintained a solid development momentum, with its FY20 annual report showing that the turnover up by 14.4% year-on-year to RMB 6.946 billion, net profit up by 30.7% to RMB 2.556 billion; bank balance, cash and realizable acceptance bills totaled RMB 3.114 billion as of December 31, 2020. The excellent performance shows that the Company has the necessary strength to support its industrial investment in innovative drugs and actively explore innovative platforms and projects in the industry.

At the same time, this model is being continuously optimized in order to make it replicable. With the emergence of the platform ecology of the Company, top advantageous resources in the industry will be absorbed, and the platform will eventually become an important birthplace of innovative products. And the value generated from continuous commercialization will in turn feed the entire ecology, and the flywheel of the Company's growth will also be fully accelerated.

From another perspective, CMS is not the "star" chased by capital, but more like a "producer" in the pharmaceutical innovation industry, who constantly incubates quality projects to meet the market demand and realize the continuous leap of its own value through the integration and optimization of industry resources.
Gelonghui Statement: The views in this article are from the original author and do not represent the views and position of Gelongghui. As a special reminder, investment decisions need to be based on independent thinking, the content of this article is for reference only, not as actual operational advice. Trade at your own risk.

Gelonghui Statement: The views in this article are from the original author and do not represent the views and position of Gelongghui. As a special reminder, investment decisions need to be based on independent thinking, the content of this article is for reference only, not as actual operational advice. Trade at your own risk.

By Gelonghui



Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Olympus Opens New Global HQ for Therapeutic Solutions Division and U.S. Medical Business

TOKYO, Apr 8, 2021 – (ACN Newswire) – Olympus Corporation ("Olympus" – Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) announced today the opening of a new facility in Westborough, MA, to serve as the global headquarters for its Therapeutic Solutions Division (TSD) and its medical business in the United States.



Olympus opens global headquarters for Therapeutic Solutions and Medical Business in Westborough, MA, U.S.


New facility features Olympus Continuum Training and Education Center and Olympus OR Innovation Center Showroom


Global Therapeutic Solutions headquarters opening in the U.S. is part of Transform Olympus initiative



Olympus has identified TSD as a strategic focus for growth and shifted its global head of TSD from Tokyo to the U.S. to have better access to a key medical industry cluster and generate growth through stronger business opportunities. Since the Transform Olympus initiatives were unveiled in 2019, many U.S.-based executives have been leading TSD growth; Olympus has dramatically expanded the business with acquisitions, as well as through organic growth.

The new 150,000-square-foot facility in Westborough will accommodate both the U.S. TSD employees and those formerly reporting to Image Stream Medical (ISM) facility located in Littleton, MA, with the exception of the manufacturing employees who will remain in Littleton. The facility will serve as one of several R&D hubs for Olympus, while enabling coordinated and agile management processes to support a global medical technology enterprise. At Olympus Westborough, the Olympus Continuum Training and Education Center will offer hands-on learning opportunities led by top medical experts using advanced medical equipment in a wetlab setting, both in person and virtually via the MedPresence telecollaboration platform. For interactions with customers and prospects, the Olympus OR Innovation Center showroom, also outfitted with the MedPresence platform, will provide an immersive environment for in-person or virtual integrated OR demonstrations.

The new Westborough facility will also provide enhanced opportunities for Olympus to build relationships with potential future employees. Olympus will facilitate relationships with potential job candidates, as well as continued partnerships with universities, colleges, and technical schools in the greater Boston area to bring world-class skills and capabilities to the company.

Nacho Abia, Chief Operating Officer of Olympus Corporation, said, "The U.S. market continues to be the largest in the world because of growing demand for minimally invasive treatment and surgery and the need for remote collaboration under COVID-19, so it's natural that we decided to combine all functions in Massachusetts in one place to facilitate agility and collaboration. This agile and globally-connected way of business will enhance our overall business competitiveness."

About Olympus' Medical business

As a leading medical technology company, our Medical business uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients and their safety. Olympus' Medical portfolio includes endoscopes, laparoscopes, and video imaging systems, as well as surgical energy devices, system integration solutions, medical services, and a wide range of endotherapy instruments for endoscopic and therapeutic applications. For more information, visit www.olympus-global.com.

For questions or additional information, please contact:

United States
Jennifer Bannan
+1 412-403-8742
jennifer.bannan@olympus.com

Europe, Middle East and Africa
Matthias Gengenbach
+49 15142369420
matthias.gengenbach@olympus-europa.com

Japan and APAC
Yuka Horimoto
+81-90-2490-1071
yuka.horimoto@olympus.com

Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Avantor Named Best Bioprocessing Supplier in Single-Use Manufacturing at Asia-Pacific Bioprocessing Excellence Awards 2021

Singapore, Apr 6, 2021 – (ACN Newswire) – Avantor Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, was named Best Bioprocessing Supplier in Single-Use Manufacturing at the Asia-Pacific Bioprocessing Excellence Awards 2021 held recently.

The award recognizes Avantor's contributions in facilitating biomanufacturing excellence with enhanced speed, reduced cost and superior quality, and reaffirms its critical role in biomanufacturing of biologics. Avantor was also awarded Best Company in Bioprocessing Excellence for Single-use Solutions at Biologics Manufacturing Korea 2020.

Narayana Rao Rapolu, Vice President, Biopharma Asia Middle East & Africa for the Company said, "Avantor has long been an open-architecture, single-use provider, offering complete design, manufacturing and logistics to support every stage of the biomanufacturing process. Our work in biopharma has never been more important. From the small-scale bench, to pilot plant and full commercial manufacturing, we enable our customers to reach the market with new treatments for patients – faster, safer and smarter."

Significance of single-use technologies:
– Robust and scalable, enabling transformative treatments to reach more patients globally.
– According to BioPharm International, a publication that integrates the science and business of biopharmaceuticals, single-use technologies are used in nearly 85% of pre-commercial manufacturing of biologics.
– Applications of biologics include monoclonal antibodies (mAbs) used in therapeutic solutions for immune-oncology and immunotherapy and cell and gene therapies which help to treat challenging illnesses, such as some cancers and genetic diseases.

For more information about Avantor's single-use solutions for biopharma manufacturing, watch this video: https://youtu.be/mfjZEfO_RVM.

About Avantor

Avantor, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. One of our greatest strengths comes from having a global infrastructure that is strategically located to support the needs of our customers. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world.

For information, visit avantorsciences.com and find us on:
LinkedIn: https://www.linkedin.com/company/avantorinc/
Twitter: https://twitter.com/Avantor_News
Facebook: https://www.facebook.com/Avantorinc/

About Asia-Pacific Bioprocessing Excellence Award 2021 (ABEA)

The Asia-Pacific Bioprocessing Excellence Awards seeks to give recognition to exceptional bioprocessing experts, organizations and technologies that facilitate biomanufacturing excellence with enhanced speed, reduced cost, and superior quality. 2021 marks the fifth year of ABEA, which was first established in 2017 and backed by industry requests.

AMEA Media Contact
Christina Koh
Director – Communications, AMEA
Avantor
Phone: +65 9170 0169
Email: Christina.Koh@avantorsciences.com

Source: Avantor and Financial News

Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com